Viridian Therapeutics IncDE
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES Power of Attorney (included on signature page hereto)
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| VIRIDIAN THERAPEUTICS, INC. | ||
| Date: February 27, 2024 | By: | /s/ Stephen Mahoney |
|---|---|---|
| Stephen Mahoney | ||
| President, Chief Executive Officer and Director | ||
| (Principal Executive Officer) | ||
| Date: February 27, 2024 | By: | /s/ Seth Harmon |
| Seth Harmon | ||
| Senior Vice President of Finance and Accounting | ||
| (Principal Financial Officer; Principal Accounting Officer) | ||
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Stephen Mahoney and Seth Harmon, and each of them, as his or her attorneys-in-fact, with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact, and each of them, or his substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of l934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Stephen Mahoney | President, Chief Executive Officer and Director | February 27, 2024 |
| Stephen Mahoney | (Principal Executive Officer) | |
| /s/ Seth Harmon | Senior Vice President of Finance and Accounting | February 27, 2024 |
| Seth Harmon | (Principal Financial Officer; Principal Accounting Officer) | |
| /s/ Tomas Kiselak | Chairman of the Board | February 27, 2024 |
| Tomas Kiselak | ||
| /s/ Sarah Gheuens | Director | February 27, 2024 |
| Sarah Gheuens, M.D., Ph.D. | ||
| /s/ Peter Harwin | Director | February 27, 2024 |
| Peter Harwin | ||
| /s/ Arlene Morris | Director | February 27, 2024 |
| Arlene Morris | ||
| /s/ Jennifer Moses | Director | February 27, 2024 |
| Jennifer Moses | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.